TICKERNOMICS Sign up
Last Update: 2024-12-27 15:23:37
Apogee Therapeutics Inc. ( APGE )
47.18USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
APGE
57.16%
SPY
32.66%
APGE
0.00%
SPY
108.59%
APGE
0.00%
SPY
302.52%
APGE
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
2679.61
2165.70
0.24
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-18.27
0.00
3.65
-4.10
0.00
-10.85
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-160.27
-76.37
0.00
Other Earnings and Cash Flow Stats:
Apogee Therapeutics Inc. ( APGE ) Net Income TTM ($MM) is -146.66
Apogee Therapeutics Inc. ( APGE ) Operating Income TTM ($MM) is -178.14
Apogee Therapeutics Inc. ( APGE ) Owners' Earnings Annual ($MM) is 0.00
Apogee Therapeutics Inc. ( APGE ) Current Price to Owners' Earnings ratio is 0.00
Apogee Therapeutics Inc. ( APGE ) EBITDA TTM ($MM) is -140.88
Apogee Therapeutics Inc. ( APGE ) EBITDA Margin is 0.00%
Capital Allocation:
Apogee Therapeutics Inc. ( APGE ) has paid 0.00 dividends per share and bought back -6.121248 million shares in the past 12 months
Apogee Therapeutics Inc. ( APGE ) has increased its debt by 12.14 million USD in the last 12 months
Capital Structure:
Apogee Therapeutics Inc. ( APGE ) Interest-bearing Debt ($MM) as of last quarter is 12
Apogee Therapeutics Inc. ( APGE ) Annual Working Capital Investments ($MM) are -57
Apogee Therapeutics Inc. ( APGE ) Book Value ($MM) as of last quarter is 734
Apogee Therapeutics Inc. ( APGE ) Debt/Capital as of last quarter is 1%
Other Balance Sheet Stats:
Apogee Therapeutics Inc. ( APGE ) has 118 million in cash on hand as of last quarter
Apogee Therapeutics Inc. ( APGE ) has 32 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Apogee Therapeutics Inc. ( APGE ) has 56 common shares outstanding as of last quarter
Apogee Therapeutics Inc. ( APGE ) has 0 million USD of preferred stock value
Academic Scores:
Apogee Therapeutics Inc. ( APGE ) Altman Z-Score is 37.88 as of last quarter
Apogee Therapeutics Inc. ( APGE ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Apogee Therapeutics Inc. ( APGE ) largest shareholder is owning shares at 0.00 ($MM) value
McKenna Mark C.(an insider) Bought 12500 shares of Apogee Therapeutics Inc. ( APGE ) for the amount of $623125.00 on 2024-12-12
11.70% of Apogee Therapeutics Inc. ( APGE ) is held by insiders, and 127.15% is held by institutions
Apogee Therapeutics Inc. ( APGE ) went public on 2023-07-14
Other Apogee Therapeutics Inc. ( APGE ) financial metrics:
FCF:-134.53
Unlevered Free Cash Flow:0.00
EPS:-3.45
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-26.70
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Apogee Therapeutics Inc. ( APGE ) :
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.